Marker Therapeutics Inc (MRKR)

I don’t think that’s right. In 2024 they said they’d provide a data update in Q4 2024 and they did (albeit one week before Christmas).
In this case they’ve also been pretty explicit: “We anticipate providing a data update from the APOLLO study in the second quarter of 2026.” (Per the 10Q in March.) I think they clearly missed that deadline. The question is why — is the data lackluster so they’re hoping it improves before disclosing, or is the data good but they want to make a splash so are taking their time.
It’s also possible the FDA meeting was delayed and they want to share the data with FDA meeting notes together. Either way, I’d be surprised if we didn’t hear something in July, since they telegraphed three things by end of a June and have said nothing about any of them. (And because Q1 2027 cash runway is getting nearer.)

So basically they told us that there is NOT any great news coming, because if the had great news, no company in their right mind would withhold it. Great news gets released.

TRUE, still sad but still true.

In my case, patience left the station a LONG time ago.

The company's previous interpretation of Q2 is Q2 earnings. So when they say we will have more information in Q2 they mean THEY will have the info and then they will probably bury it in their Q2 results that come out a month and a half later for all us plebs to view. They have made it very clear they have no regard for their shareholders.

Amen, let’s hope not, it is very frustrating, you need a lot of patience in biotech

I just hope that they don't tell us, for about the 20th time, about the first 2 patients they dosed like 4 YEARS AGO.

Are we having a head fake? Or could there be possible news coming out? We are definitely overdue for news.

So, do we have 2 days left before we are supposed to get some announcement or data or updates?
Something, Anything, corporate news on where the company officers will be vacationing this summer,
amount of next years bonuses approved.
Of course, something more along the lines of what we were told would happen, would also be nice.
Doctor Vera - THANK YOU FOR YOUR ATTENTION TO THIS MATTER.

when speaking of Vera, you need to verify what he is talking about because sometimes his mind wonders. so, for example, when he said Apollo, was he referring to the space program or maybe the movie Rocky?
if it was Marker, we would have gotten our answer by now.

After about 30 YEARS in TPIV and MRKR,
I don't even care anymore.
Made so much $ in NVDA, MU, SNDK, CRDO, AVGO,
and many many others in the last several years buying both shares and leap call options, MRKR has become kind of irrelevant at this point.

TICK TICK TICK

Vera told investors to expect three things in Q2: (1) APOLLO update in DLBCL, maximum dose level, (2) FDA feedback on APOLLO study design, potentially a pivotal Phase 2, and (3) initiation of the company-sponsored pancreatic trial. Do we think he’ll deliver on any of them? A little over 1 week left in June and feels like we could end the month at either $4 or sub-$1.

Vera hasn’t even had a talk this year?

The Great Disappearing Act going on here. LOL.

…Maybe he’s at the soccer game?

Feels like Vera’s just collecting a paycheck. 🔬

TICK TICK - YAWN YAWN - OH WHAT A BIG BORE IT IS.
ok, time to click the green bull icon - you know - just for yucks.

i highly doubt the $8 PT.
However, if in June the sp does steadily move and break $2, we might stand a chance.
Remember there are warrants around $4 ish. that's a bummer right there.
Whatever is coming has to be exceedingly good to storm pass that.
And i don't believe they have it in them.
there are a bunch of jokers led by chief clown Vera.

AlloVir, TapImmune, Marker. Got to do more than that.

“Well, we can all cling to the only thing that is left.
Blind Hope.”

Well, we can all cling to the only thing that is left.
Blind Hope.

SAD, just so Very sad.

What do you mean meaningless!?!?!! SP is going to jump on increased volume, then within a week give up all gains to fall below the SP before the news hit and sit there for months while the company sits on their hands and does nothing.

Yea I guess your right.

Classic CG / HCW analysts seeking banking business, but still:
Buy Rating Reaffirmed on Marker Therapeutics as Clinical Milestones Near; $8 Price Target Maintained
Analyst John Newman of Canaccord Genuity maintained a Buy rating on Marker Therapeutics, retaining the price target of $8.00.
John Newman’s rating is based on the view that upcoming clinical and regulatory milestones could significantly enhance Marker Therapeutics’ valuation while the risk profile remains manageable. He highlights the forthcoming APOLLO trial update in 2Q26, where additional patients and longer follow-up may confirm strong response and durability signals in a difficult, late-line non-Hodgkin’s lymphoma population, supporting confidence in MT-601’s potential.
He also points to anticipated alignment with the FDA on a pivotal, single-arm Phase 2 study in third-line DLBCL, which could provide a relatively efficient registration path. In addition, the grant-funded pancreatic cancer trial and the ongoing off-the-shelf MT-401 program in AML offer diversified upside, while the current cash runway into 1Q27 and the capacity to raise additional capital support continued development, justifying his unchanged $8 price target and Buy rating.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.

Needed a real dynamic CEO but shareholders voted for the same old. 🤷🏻‍♂️

I don't know when it will be, but I suspect that any data update / FDA trial design notes will be meaningless for the share price.

What do folks think, do we get the data update / FDA trial design notes before 6/30 or will Vera wait until the absolute end of Q2?

New pancreatic cancer pill could reshape treatment as early trial results stun researchers.
https://www.foxnews.com/health/new-pancreatic-cancer-pill-could-reshape-treatment-early-trial-results-stun-researchers

Looks like everyone passed away here? They need to invent a T cell for investors.

Somehow Vera got the votes. 🤷🏻‍♂️🤔🐑

At some point Baylor says WTF and takes back the tech which may be the plan anyway?

Unless they get a FDA approval, it's worth about a cup of coffee.

I wish they would sell the company. Do you guys think we can get anything for it? Thank you for any response.

Seriously, I just can not take this excitement anymore.

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer.
REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced positive topline results from its global, randomized, controlled Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had been previously treated. Daraxonrasib taken orally once daily demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared with standard of care cytotoxic chemotherapy delivered intravenously. In the overall (intent-to-treat) study population, daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001). Daraxonrasib was generally well tolerated, with a manageable safety profile and with no new safety signals.Click here for full release.

Press Releases
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
Just more of the same old data.

A friend of mine said he did that and said not only were the lights on but there seemed to be a party going on. Everyone dancing and loud rock music through the windows. Holding one guy upside down as he guzzled from a keg but he couldn't tell if CEO. I have no way to check accuracy....

can somebody do a drive by and see if the lights are on?
and check on the whereabouts of Vera.
is he alive, and is he still the CEO?
or did they just close down and forgot to tell Nasdaq 🤔

Any opinions on the proposals for the shareholders meetings? Does it really matter if I vote no, going from 30 million shares, to 130 million shares really sucks. does anybody think any of this is good? Thank you.

Sad seeing the culmination of three biotechs total just $23M market cap, or the salary of a good baseball player. Way to go Vera!

Sorry, my apologies, the company moved up the shareholders annual meeting. I’m thinking a clinical data read out and partnership announcement. Let’s hope.🙏🏼🙏🏼

The annual shareholders meeting has been pushed back to May 1, any opinions on this? thank you.

Anyone here sending in proposals?

>>On February 9, 2026, Marker Therapeutics, Inc. announced that its Board of Directors had set May 1, 2026 as the date for the company’s 2026 Annual Meeting of Stockholders, a move that advances the meeting more than 30 days from the prior year’s schedule and triggers specific disclosure requirements under securities regulations. As a result, the company established March 9, 2026 as the new deadline for stockholder proposals to be included in the 2026 proxy materials and directed investors to submit such proposals to its Houston corporate offices, with the record date, time and location of the meeting to be detailed in the forthcoming proxy statement.

>>On February 9, 2026, the Board of Directors of Marker Therapeutics, Inc. (the “Company”) determined it is in the best interest of the Company to schedule Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) for May 1, 2026. Because the date of the 2026 Annual Meeting has advanced by more than 30 days from the anniversary date of the Company’s 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”), in accordance with Rule 14a-18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company is informing stockholders of such change and that, accordingly, a new deadline has been set for submission of proposals by Stockholders intended to be included in the Company’s 2026 proxy statement and form of proxy. Proposals to be included in the Company’s proxy statement for the 2026 Annual Meeting in accordance with Rule 14a-8 under the Exchange Act must be received by the Company on or before March 9, 2026, which the Company believes is a reasonable time before it expects to begin to print and send its proxy materials. Stockholders must deliver the proposals or nominations to the Company’s principal executive offices at the following address: Marker Therapeutics, Inc., Attn: Corporate Secretary, 2450 Holcombe Blvd, TMC Partners Office 1.311, Houston, Texas 77021. The record date, time and location of the 2026 Annual Meeting will be as set forth in the Company’s proxy statement for the 2026 Annual Meeting.

????
NovoCure confirms FDA approval of Optune Pax for the treatment of locally advanced pancreatic cancer
05:33:50 PM ET, 02/11/2026 - Briefing.com
Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer. Phase 3 PANOVA-3 trial showed a statistically significant improvement in overall survival (OS) and significantly extended time to pain progression in patients treated with Optune. PaxOptune Pax is a wearable medical device that delivers Tumor Treating Fields (TTFields), alternating electric fields that disrupt cancer cell replication to cause cell death, providing a new treatment approach for pancreatic tumors.
????

Still sitting at a horrendous $28M market cap like it’s run only for researches sake by a lab rat.

Disappointing to see it back here again.

Great press. The language is a little flat for investors talking about further research. Vera needs to spruce things up in the IR department.

Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company with the worldwide exclusive license of Multi-Antigen Targeted T cells (also referred to as Multi-Antigen Recognizing T cells, or MAR-T cells, by Marker), a technology developed at Baylor College of Medicine for the treatment of hematologic and solid tumors, today announced that Baylor College of Medicine’s TACTOPS clinical study in pancreatic cancer was featured on Good Morning America on Thursday, January 22, 2026.
The segment spotlighted the Baylor-led research recently published in Nature Medicine evaluating autologous Multi-Antigen Targeted T cell therapy in patients with pancreatic ductal adenocarcinoma (PDAC) and highlighted the potential of Multi-Antigen Targeted approaches to address a significant unmet need in pancreatic cancer (Musher B et al, Nature Medicine, 2026).

“We are honored to see the Baylor pancreatic cancer study receive national attention,” said Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics. “We congratulate Dr. Ann Leen, Dr. Benjamin Musher, and the Baylor research team on advancing this important work, and we appreciate the opportunity to help raise awareness of innovative cell therapy approaches being explored for patients facing pancreatic cancer. We believe this visibility underscores the promise of MAR-T cells and the importance of continued clinical development to improve patient outcomes.”

As previously reported, the Phase 1/2 pancreatic cancer study conducted at Baylor College of Medicine demonstrated a favorable safety profile and showed up to 84.6% disease control rate when combining Multi-Antigen Targeted T cells with frontline chemotherapy in Arm A, with the research group also highlighting a correlation between clinical benefit and the expansion and persistence of infused T cells. In Arm A, the median duration of response for patients achieving a partial or complete response was 7.5 months (range 3.5 – 16.6) and median overall survival was 14.1 months. Investigators also reported that infused T cells were detected up to 12 months post-treatment and were observed at higher frequencies in patients who responded.

Building on this encouraging Baylor clinical study, Marker seeks now to recapitulate or potentially improve upon these results in an upcoming Company-sponsored study (ClinicalTrials.gov identifier: NCT06549751) by increasing the target antigen profile, using higher cell doses and incorporating lymphodepletion to further promote T cell expansion. The Company has received funding from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program and the Cancer Prevention and Research Institute of Texas (CPRIT) and anticipates clinical initiation of the pancreatic cancer program in the first half of 2026.

Broadcast Details
Program: Good Morning America (ABC)
Aired: Thursday, January 22, 2026
Segment Link: https://www.goodmorningamerica.com/video/129449690

About MAR-T cells
The multi-antigen recognizing (MAR) T cell platform (formerly known as multiTAA-specific T cells) is a novel, non-genetically modified cell therapy approach that selectively expands tumor-specific T cells from a patient's/donor’s blood capable of recognizing a broad range of tumor antigens. Unlike other T cell therapies, MAR-T cells allow the recognition of hundreds of different epitopes within up to six tumor-specific antigens, thereby reducing the possibility of tumor escape. Since MAR-T cells are not genetically engineered, Marker believes that its product candidates will be easier and less expensive to manufacture, with an improved safety profile compared to current engineered T cell approaches and may provide patients with meaningful clinical benefits.

About MT-601
The Company’s lead product, MT-601, is a multi-antigen recognizing (MAR) T cell product that utilizes a non-genetically modified approach that specifically targets six different tumor antigens upregulated in tumor cells (Survivin, PRAME, WT-1, NY-ESO-1, SSX-2, MAGEA-4). Marker is currently investigating MT-601 in the Phase 1 APOLLO trial (clinicaltrials.gov identifier: NCT05798897) for the treatment of patients with lymphoma who have relapsed after or are ineligible to receive anti-CD19 CAR-T cell therapies. Due to the broad target recognition profile of MT-601, the Company is exploring its potential application beyond lymphoma in patients with pancreatic cancer. The Company’s pancreatic cancer program is supported by the National Cancer Institute of the National Institutes of Health (Award Number R44CA295168), and the Cancer Prevention and Research Institute of Texas (CPRIT, Award Number DP250150).

About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The Company was founded at Baylor College of Medicine, and clinical trials that enrolled more than 200 patients across various hematological and solid tumor indications showed that the Company’s autologous and allogeneic MAR-T cell products were well tolerated and demonstrated durable clinical responses. Marker’s goal is to introduce novel T cell therapies to the market and improve patient outcomes. To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence. Marker’s unique T cell platform is strengthened by non-dilutive funding from U.S. state and federal agencies supporting cancer research.

To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.